F2F Discussions

PTCMA Discussions

The intention with these events is to view the treatment of a disease from a clinical and funding perspective and allow for a productive and respectful discussion between representatives from the pharmaceutical, medical technology, clinical and funding industries that can lead to guidelines on when and where treatment can be reimbursed that it is most appropriate and realistic.

How will it look like?

Suggested programme

Times may differ according to discussions with programme contributors.

07h30 Networking and refreshments
08h00 Welcoming and sharing of meeting intent
08h10 Clinical discussion
08h40 Health Economic analyses summary
09h00 Funding discussion - global and local guidelines
09h20 Funding discussion - funding challenges
09h40 Provider discussion - pricing process
10h00 Panel Discussion
10h30 Close

Clinical presentation requirements

Presenter should:

  • have an academic association or have been involved in clinical trials,
  • have a passion for the patient,
  • be reasonably pragmatic – someone who understands that we want to get to a best-case scenario rather than a perfect solution.

Presentation should include:

  • information on the treatment,
  • how it compares to other standard treatments,
  • the outcomes,
  • timelines of treatment,
  • which cohort of patients it would be most beneficial.

The intention is to present facts and outcomes that can form the foundation for the rest of the discussions.

Health Economic Analysis

An independent presenter gives a summary on findings of Health Economic Analyses on the treatment under discussion.

  • What type of health economic analysis was used and why,
  • share the direct costs of treatment in the short and long term,
  • share the indirect costs involved.

Funding presentation requirements

  • Share what the treatment and reimbursement guidelines are in other countries compared to South Africa,
  • share the challenges funders are facing in applying these guidelines,
  • share realistic possible solutions to these challenges.

The reality is that there are patients that require treatment that far outweighs their monthly contributions, resulting in funders needing to be responsible stewards in reimbursing as many members as they can in the place they need it most. The intention is to view the treatment of the disease from a funding perspective and together with the clinical perspective, open up for a discussion that can lead to guidelines on when and where treatment can be reimbursed that it is most appropriate and realistic.

Provider discussion

A representative from the pharmaceutical or medical technology provider discusses:

  • Possible challenges in pricing,
  • what flexibility there might be in the pricing.

After all is said and done, every part of the healthcare industry, the clinicians, funders and providers, will all need to compromise. Can we come together and discuss how we can all work together for the good of the patient?

Process

4 months prior
3 months prior
Lead-up to event - 8 weeks prior
Event day
Week after

Pre-planning discussion

Once the suggestion is approved by the PTCMA Education Task Team, the PTCMA will arrange a Teams meeting between the sponsors, PTCMA Management Team and Education Task Team representative, to discuss the expectation, and information shared on the form.

If all are in agreement, the PTCMA will share an event proposal to be signed by the sponsors to formalise the meeting.

Programme check-ins

As the programme is confirmed, have two-weekly check-ins as is appropriate for presenters to understand the requirements, arrange the practicalities, etc.

Face-to-face discussion

Event takes place:

  • PTCMA manages registrations, etc
  • There is catering for before and after with a quick coffee break in the middle
  • Chairperson opens the meeting and introduces the presenters
  • Panel discussion is facilitated by the chairperson and all the contributors serve on the panel
  • Networking opportunity before and after session
  • A event survey is shared before closing off the session to get feedback.

Debriefing

  • Discuss feedback from all contributors
  • Share feedback from delegates
  • Discuss any possible further action points.

Costing

  • Corporate Members

    Exclusive sponsorship:
    R40 300.00

    Co-sponsorship:
    R20 150.00

  • Standard Members

    Exclusive sponsorship:
    R64 480.00

    Co-sponsorship:
    R32 240.00

  • Non Members

    Exclusive sponsorship:
    R80 600.00

    Co-sponsorship:
    R40 300.00

Includes:

  • Honoraria of R5 600 included for Clinical Presenter
  • Panel of funding presenters
  • Full facilitation of 2-3 hour session
  • Hosted in JHB, CPT or PTA
  • Programme coordination
  • Venue costs
  • Catering
  • Video conferencing to funders in other regions
  • Recording
  • CPD accreditation
  • Sponsor allowed banners at venue outside of meeting room & acknowledgment in event programme
  • Excludes travel costs

Recording and hosting – included

  • Copy sent to sponsor
  • Hosted on secure PTCMA Portal for 12 months
  • Open to all PTCMA members and clinicians registered with HPCSA
  • Includes coupon for 50 individual accesses for non-members

Suggest an event

PLEASE NOTE: Completing this form is just a suggestion and does not constitute a booking. The PTCMA will reach out to discuss feasibility, capacity and availability based on the information provided.

Scheduled Events

Please note that dates, topics and presenters are subject to change.

Latest Newsletter

Find us on